47 results on '"Herbert, Andrew S."'
Search Results
2. Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38
- Author
-
Shin, Olivia S., Monticelli, Stephanie R., Hjorth, Christy K., Hornet, Vladlena, Doyle, Michael, Abelson, Dafna, Kuehne, Ana I., Wang, Albert, Bakken, Russell R., Mishra, Akaash K., Middlecamp, Marissa, Champney, Elizabeth, Stuart, Lauran, Maurer, Daniel P., Li, Jiannan, Berrigan, Jacob, Barajas, Jennifer, Balinandi, Stephen, Lutwama, Julius J., Lobel, Leslie, Zeitlin, Larry, Walker, Laura M., Dye, John M., Chandran, Kartik, Herbert, Andrew S., Pauli, Noel T., and McLellan, Jason S.
- Published
- 2024
- Full Text
- View/download PDF
3. Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described Cohort
- Author
-
Taylor, Kevin M., Ricks, Keersten M., Kuehnert, Paul A., Eick-Cost, Angelia A., Scheckelhoff, Mark R., Wiesen, Andrew R., Clements, Tamara L., Hu, Zheng, Zak, Samantha E., Olschner, Scott P., Herbert, Andrew S., Bazaco, Sara L., Creppage, Kathleen E., Fan, Michael T., and Sanchez, Jose L.
- Published
- 2023
- Full Text
- View/download PDF
4. Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein
- Author
-
Caohuy, Hung, Eidelman, Ofer, Chen, Tinghua, Mungunsukh, Ognoon, Yang, Qingfeng, Walton, Nathan I., Pollard, Bette S., Khanal, Sara, Hentschel, Shannon, Florez, Catalina, Herbert, Andrew S., and Pollard, Harvey B.
- Published
- 2024
- Full Text
- View/download PDF
5. Development of an antibody cocktail for treatment of Sudan virus infection
- Author
-
Herbert, Andrew S., Froude, Jeffery W., Ortiz, Ramon A., Kuehne, Ana I., Dorosky, Danielle E., Bakken, Russell R., Zak, Samantha E., Josleyn, Nicole M., Musiychuk, Konstantin, Jones, R. Mark, Green, Brian, Streatfield, Stephen J., Wec, Anna Z., Bohorova, Natasha, Bohorov, Ognian, Kim, Do H., Pauly, Michael H., Velasco, Jesus, Whaley, Kevin J., Stonier, Spencer W., Bornholdt, Zachary A., Chandran, Kartik, Zeitlin, Larry, Sampey, Darryl, Yusibov, Vidadi, and Dye, John M.
- Published
- 2020
6. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
- Author
-
Wirchnianski, Ariel S., Nyakatura, Elisabeth K., Herbert, Andrew S., Kuehne, Ana I., Abbasi, Shawn A., Florez, Catalina, Storm, Nadia, McKay, Lindsay G. A., Dailey, Leandrew, Kuang, Erin, Abelson, Dafna M., Wec, Anna Z., Chakraborti, Srinjoy, Holtsberg, Frederick W., Shulenin, Sergey, Bornholdt, Zachary A., Aman, M. Javad, Honko, Anna N., Griffiths, Anthony, and Dye, John M.
- Subjects
BISPECIFIC antibodies ,MARBURG virus ,EBOLA virus ,HEMORRHAGIC fever ,FILOVIRIDAE ,PROTEIN engineering - Abstract
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation. Here, we explore a bsAb strategy for generation of pan-ebolavirus and pan-filovirus immunotherapeutics. Filoviruses, including Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV), cause severe hemorrhagic fever. Although there are two FDA-approved mAb therapies for EBOV infection, these do not extend to other filoviruses. Here, we combine Fvs from broad ebolavirus mAbs to generate novel pan-ebolavirus bsAbs that are potently neutralizing, confer protection in mice, and are resistant to viral escape. Moreover, we combine Fvs from pan-ebolavirus mAbs with those of protective MARV mAbs to generate pan-filovirus protective bsAbs. These results provide guidelines for broad antiviral bsAb design and generate new immunotherapeutic candidates. Author summary: Filoviruses, such as Ebola virus and Marburg virus (EBOV and MARV, respectively), cause severe hemorrhagic fever with a high mortality rate in humans. Monoclonal antibodies (mAbs) are effective treatments for filovirus infection, but current therapies have limited breadth. Furthermore, a single mAb is susceptible to development of resistance. Here, we used protein engineering to create "bispecific" antibodies in which activities of two different mAbs were combined into one. These bispecific antibodies had broad activity, in one case providing protection against lethal challenge by two distant clades of filoviruses (EBOV and MARV). The bispecific antibodies were also less susceptible to resistance mutations. This work provides a roadmap for development of new bispecific antibody therapies for filoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors
- Author
-
Sobarzo, Ariel, Stonier, Spencer W., Radinsky, Olga, Gelkop, Sigal, Kuehne, Ana I., Edri, Avishay, Herbert, Andrew S., Fedida-Metula, Shlomit, Lutwama, Julius Julian, Yavelsky, Victoria, Davis, Claytus, Porgador, Angel, Dye, John M., and Lobel, Leslie
- Published
- 2019
- Full Text
- View/download PDF
8. SARS-CoV-2 Aerosol and Intranasal Exposure Models in Ferrets.
- Author
-
Zumbrun, Elizabeth E., Zak, Samantha E., Lee, Eric D., Bowling, Philip A., Ruiz, Sara I., Zeng, Xiankun, Koehler, Jeffrey W., Delp, Korey L., Bakken, Russel R., Hentschel, Shannon S., Bloomfield, Holly A., Ricks, Keersten M., Clements, Tamara L., Babka, April M., Dye, John M., and Herbert, Andrew S.
- Subjects
SARS-CoV-2 ,MICROBIOLOGICAL aerosols ,FERRET ,TURBINATE bones ,VIRAL antigens - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the worldwide COVID-19 pandemic. Animal models are extremely helpful for testing vaccines and therapeutics and for dissecting the viral and host factors that contribute to disease severity and transmissibility. Here, we report the assessment and comparison of intranasal and small particle (~3 µm) aerosol SARS-CoV-2 exposure in ferrets. The primary endpoints for analysis were clinical signs of disease, recovery of the virus in the upper respiratory tract, and the severity of damage within the respiratory tract. This work demonstrated that ferrets were productively infected with SARS-CoV-2 following either intranasal or small particle aerosol exposure. SARS-CoV-2 infection of ferrets resulted in an asymptomatic disease course following either intranasal or small particle aerosol exposure, with no clinical signs, significant weight loss, or fever. In both aerosol and intranasal ferret models, SARS-CoV-2 replication, viral genomes, and viral antigens were detected within the upper respiratory tract, with little to no viral material detected in the lungs. The ferrets exhibited a specific IgG immune response to the SARS-CoV-2 full spike protein. Mild pathological findings included inflammation, necrosis, and edema within nasal turbinates, which correlated to positive immunohistochemical staining for the SARS-CoV-2 virus. Environmental sampling was performed following intranasal exposure of ferrets, and SARS-CoV-2 genomic material was detected on the feeders and nesting areas from days 2–10 post-exposure. We conclude that both intranasal and small particle aerosol ferret models displayed measurable parameters that could be utilized for future studies, including transmission studies and testing SARS-CoV-2 vaccines and therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Structural basis of broad ebolavirus neutralization by a human survivor antibody
- Author
-
West, Brandyn R., Wec, Anna Z., Moyer, Crystal L., Fusco, Marnie L., Ilinykh, Philipp A., Huang, Kai, Wirchnianski, Ariel S., James, Rebekah M., Herbert, Andrew S., Hui, Sean, Goodwin, Eileen, Howell, Katie A., Kailasan, Shweta, Aman, M. Javad, Walker, Laura M., Dye, John M., Bukreyev, Alexander, Chandran, Kartik, and Saphire, Erica Ollmann
- Published
- 2019
- Full Text
- View/download PDF
10. Protocadherin-1 is essential for cell entry by New World hantaviruses
- Author
-
Jangra, Rohit K., Herbert, Andrew S., Li, Rong, Jae, Lucas T., Kleinfelter, Lara M., Slough, Megan M., Barker, Sarah L., Guardado-Calvo, Pablo, Román-Sosa, Gleyder, Dieterle, M. Eugenia, Kuehne, Ana I., Muena, Nicolás A., Wirchnianski, Ariel S., Nyakatura, Elisabeth K., Fels, J. Maximilian, Ng, Melinda, Mittler, Eva, Pan, James, Bharrhan, Sushma, Wec, Anna Z., Lai, Jonathan R., Sidhu, Sachdev S., Tischler, Nicole D., Rey, Félix A., Moffat, Jason, Brummelkamp, Thijn R., Wang, Zhongde, Dye, John M., and Chandran, Kartik
- Published
- 2018
- Full Text
- View/download PDF
11. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses
- Author
-
Wec, Anna Z., Nyakatura, Elisabeth K., Herbert, Andrew S., Howell, Katie A., Holtsberg, Frederick W., Bakken, Russell R., Mittler, Eva, Christin, John R., Shulenin, Sergey, Jangra, Rohit K., Bharrhan, Sushma, Kuehne, Ana I., Bornholdt, Zachary A., Flyak, Andrew I., Saphire, Erica Ollmann, Crowe, James E., Aman, M. Javad, Dye, John M., Lai, Jonathan R., and Chandran, Kartik
- Published
- 2016
12. Novel Small Molecule Entry Inhibitors of Ebola Virus
- Author
-
Basu, Arnab, Mills, Debra M., Mitchell, Daniel, Ndungo, Esther, Williams, John D., Herbert, Andrew S., Dye, John M., Moir, Donald T., Chandran, Kartik, Patterson, Jean L., Rong, Lijun, and Bowlin, Terry L.
- Published
- 2015
13. Lassa virus entry requires a trigger-induced receptor switch
- Author
-
Jae, Lucas T., Raaben, Matthijs, Herbert, Andrew S., Kuehne, Ana I., Wirchnianski, Ariel S., Soh, Timothy K., Stubbs, Sarah H., Janssen, Hans, Damme, Markus, Saftig, Paul, Whelan, Sean P., Dye, John M., and Brummelkamp, Thijn R.
- Published
- 2014
14. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
- Author
-
Dye, John M., Herbert, Andrew S., Kuehne, Ana I., Barth, James F., Muhammad, Majidat A., Zak, Samantha E., Ortiz, Ramon A., Prugar, Laura I., and Pratt, William D.
- Published
- 2012
15. Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets
- Author
-
Clinton, Tracy R., Weinstock, Matthew T., Jacobsen, Michael T., Szabo-Fresnais, Nicolas, Pandya, Maya J., Whitby, Frank G., Herbert, Andrew S., Prugar, Laura I., McKinnon, Rena, Hill, Christopher P., Welch, Brett D., Dye, John M., Eckert, Debra M., and Kay, Michael S.
- Published
- 2015
- Full Text
- View/download PDF
16. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
- Author
-
Carette, Jan E., Raaben, Matthijs, Wong, Anthony C., Herbert, Andrew S., Obernosterer, Gregor, Mulherkar, Nirupama, Kuehne, Ana I., Kranzusch, Philip J., Griffin, April M., Ruthel, Gordon, Cin, Paola Dal, Dye, John M., Whelan, Sean P., Chandran, Kartik, and Brummelkamp, Thijn R.
- Published
- 2011
- Full Text
- View/download PDF
17. VIRUS ENTRY: Lassa virus entry requires a trigger-induced receptor switch
- Author
-
Jae, Lucas T., Raaben, Matthijs, Herbert, Andrew S., Kuehne, Ana I., Wirchnianski, Ariel S., Soh, Timothy K., Stubbs, Sarah H., Janssen, Hans, Damme, Markus, Saftig, Paul, Whelan, Sean P., Dye, John M., and BrummeIkamp, Thijn R.
- Published
- 2014
- Full Text
- View/download PDF
18. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
- Author
-
Ciencewicki, Jonathan M, Herbert, Andrew S, Storm, Nadia, Josleyn, Nicole M, Huie, Kathleen E, McKay, Lindsay G A, Griffiths, Anthony, Dye, John M, Willis, Todd, and Arora, Vikram
- Subjects
- *
CONVALESCENT plasma , *EBOLA virus disease , *ANTIBODY titer , *VIRUS diseases , *ENZYME-linked immunosorbent assay , *RESEARCH , *ANIMAL experimentation , *BLOOD plasma , *EVALUATION research , *EBOLA virus , *INTRAVENOUS immunoglobulins , *COMPARATIVE studies , *RESEARCH funding , *VIRAL antibodies , *MICE - Abstract
Background: Convalescent plasma has been used to treat many viral diseases including Ebola. The manufacture of a purified anti-Ebola virus (EBOV) intravenous immunoglobulin (IVIG) from pooled convalescent plasma is described in this paper.Methods: An enzyme-linked immunosorbent assay (ELISA) targeting an EBOV surface glycoprotein antigen was used to determine the immunoglobulin titer of pooled plasma and purified anti-EBOV IVIG. Anti-EBOV IVIG was also tested in neutralization assays using a vesicular stomatitis virus pseudovirion expressing EBOV glycoprotein on its surface and with live EBOV. Finally, the efficacy of the anti-EBOV IVIG was assessed in a mouse model of EBOV infection.Results: In the ELISA, the anti-EBOV IVIG was shown to have a 7-fold increase in immunoglobulin G (IgG) titer over pooled convalescent plasma. In both the pseudovirion and live virus assays, the anti-EBOV IVIG showed approximately 5- to 6-fold increased potency over pooled plasma. Anti-EBOV IVIG also significantly improved survivability in mice infected with the virus when administered concurrently or 2 days after infection.Conclusions: These data support this purified anti-EBOV IVIG merits additional investigation and clinical trials for treatment and postexposure prophylaxis of Ebola virus disease. The experience gained can be applied to manufacture hyperimmune globulins against other emerging viruses. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
- Author
-
Wirchnianski, Ariel S., Wec, Anna Z., Nyakatura, Elisabeth K., Herbert, Andrew S., Slough, Megan M., Kuehne, Ana I., Mittler, Eva, Jangra, Rohit K., Teruya, Jonathan, Dye, John M., Lai, Jonathan R., and Chandran, Kartik
- Subjects
BISPECIFIC antibodies ,IMMUNOGLOBULINS ,MONOCLONAL antibodies ,THERAPEUTICS ,EBOLA virus - Abstract
Multiple agents in the family Filoviridae (filoviruses) are associated with sporadic human outbreaks of highly lethal disease, while others, including several recently identified agents, possess strong zoonotic potential. Although viral glycoprotein (GP)-specific monoclonal antibodies have demonstrated therapeutic utility against filovirus disease, currently FDA-approved molecules lack antiviral breadth. The development of broadly neutralizing antibodies has been challenged by the high sequence divergence among filovirus GPs and the complex GP proteolytic cleavage cascade that accompanies filovirus entry. Despite this variability in the antigenic surface of GP, all filoviruses share a site of vulnerability—the binding site for the universal filovirus entry receptor, Niemann-Pick C1 (NPC1). Unfortunately, this site is shielded in extracellular GP and only uncovered by proteolytic cleavage by host proteases in late endosomes and lysosomes, which are generally inaccessible to antibodies. To overcome this obstacle, we previously developed a 'Trojan horse' therapeutic approach in which engineered bispecific antibodies (bsAbs) coopt viral particles to deliver GP:NPC1 interaction-blocking antibodies to their endo/lysosomal sites of action. This approach afforded broad protection against members of the genus Ebolavirus but could not neutralize more divergent filoviruses. Here, we describe next-generation Trojan horse bsAbs that target the endo/lysosomal GP:NPC1 interface with pan-filovirus breadth by exploiting the conserved and widely expressed host cation-independent mannose-6-phosphate receptor for intracellular delivery. Our work highlights a new avenue for the development of single therapeutics protecting against all known and newly emerging filoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge
- Author
-
Roberts Paul C, Sundick Roy, Heffron Lynn, and Herbert Andrew S
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Influenza epidemics continue to cause morbidity and mortality within the human population despite widespread vaccination efforts. This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. We have developed an in vitro model system for producing a membrane-bound Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines and other immunomodulatory proteins to create a more immunogenic vaccine. Results We have evaluated the immunogenicity of inactivated cytokine-bearing influenza vaccines using a mouse model of lethal influenza virus challenge. CYT-IVACs were produced by stably transfecting MDCK cell lines with mouse-derived cytokines (GM-CSF, IL-2 and IL-4) fused to the membrane-anchoring domain of the viral hemagglutinin. Influenza virus replication in these cell lines resulted in the uptake of the bioactive membrane-bound cytokines during virus budding and release. In vivo efficacy studies revealed that a single low dose of IL-2 or IL-4-bearing CYT-IVAC is superior at providing protection against lethal influenza challenge in a mouse model and provides a more balanced Th1/Th2 humoral immune response, similar to live virus infections. Conclusion We have validated the protective efficacy of CYT-IVACs in a mammalian model of influenza virus infection. This technology has broad applications in current influenza virus vaccine development and may prove particularly useful in boosting immune responses in the elderly, where current vaccines are minimally effective.
- Published
- 2009
- Full Text
- View/download PDF
21. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
- Author
-
Rappazzo, C. Garrett, Tse, Longping V., Kaku, Chengzi I., Wrapp, Daniel, Sakharkar, Mrunal, Huang, Deli, Deveau, Laura M., Yockachonis, Thomas J., Herbert, Andrew S., Battles, Michael B., O’Brien, Cecilia M., Brown, Michael E., Geoghegan, James C., Belk, Jonathan, Peng, Linghang, Yang, Linlin, Hou, Yixuan, Scobey, Trevor D., Burton, Dennis R., and Nemazee, David
- Published
- 2021
- Full Text
- View/download PDF
22. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
- Author
-
Chan, Kui K., Dorosky, Danielle, Sharma, Preeti, Abbasi, Shawn A., Dye, John M., Kranz, David M., Herbert, Andrew S., and Procko, Erik
- Published
- 2020
- Full Text
- View/download PDF
23. Broad neutralization of SARS-related viruses by human monoclonal antibodies.
- Author
-
Wec, Anna Z., Wrapp, Daniel, Herbert, Andrew S., Maurer, Daniel P., Haslwanter, Denise, Sakharkar, Mrunal, Jangra, Rohit K., Dieterle, M. Eugenia, Lilov, Asparouh, Huang, Deli, Tse, Longping V., Johnson, Nicole V., Hsieh, Ching-Lin, Wang, Nianshuang, Nett, Juergen H., Champney, Elizabeth, Burnina, Irina, Brown, Michael, Lin, Shu, and Sinclair, Melanie
- Published
- 2020
- Full Text
- View/download PDF
24. Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.
- Author
-
Lennemann, Nicholas J., Herbert, Andrew S., Brouillette, Rachel, Rhein, Bethany, Bakken, Russell A., Perschbacher, Katherine J., Cooney, Ashley L., Miller-Hunt, Catherine L., Ten Eyck, Patrick, Biggins, Julia, Olinger, Gene, Dye, John M., and Maury, Wendy
- Subjects
- *
VESICULAR stomatitis , *EBOLA virus , *GLYCOPROTEINS , *EBOLA virus disease vaccines , *FILOVIRIDAE , *GLYCOSYLATION - Abstract
The recent Ebola virus (EBOV) epidemic in West Africa demonstrates the potential for a significant public health burden caused by filoviral infections. No vaccine or antiviral is currently FDA approved. To expand the vaccine options potentially available, we assessed protection conferred by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack native G glycoprotein (VSVΔG) and bear EBOV glycoprotein (GP). These pseudovirions mediate a single round of infection. Both single-dose and prime/boost vaccination regimens protected mice against lethal challenge with mouse-adapted Ebola virus (ma-EBOV) in a dose-dependent manner. The prime/boost regimen provided significantly better protection than a single dose. As N-linked glycans are thought to shield conserved regions of the EBOV GP receptor-binding domain (RBD), thereby blocking epitopes within the RBD, we also tested whether VSVΔG bearing EBOV GPs that lack GP1 N-linked glycans provided effective immunity against challenge with ma-EBOV or a more distantly related virus, Sudan virus. Using a prime/boost strategy, high doses of GP/VSVΔG partially or fully denuded of N-linked glycans on GP1 protected mice against ma-EBOV challenge, but these mutants were no more effective than wild-type (WT) GP/VSVΔG and did not provide cross protection against Sudan virus. As reported for other EBOV vaccine platforms, the protection conferred correlated with the quantity of EBOV GP-specific Ig produced but not with the production of neutralizing antibodies. Our results show that EBOV GP/VSVΔG pseudovirions serve as a successful vaccination platform in a rodent model of Ebola virus disease and that GP1 N-glycan loss does not influence immunogenicity or vaccination success. IMPORTANCE The West African Ebola virus epidemic was the largest to date, with more than 28,000 people infected. No FDA-approved vaccines are yet available, but in a trial vaccination strategy in West Africa, recombinant, infectious VSV encoding the Ebola virus glycoprotein effectively prevented virus-associated disease. VSVΔG pseudovirion vaccines may prove as efficacious and have better safety, but they have not been tested to date. Thus, we tested the efficacy of VSVΔG pseudovirions bearing Ebola virus glycoprotein as a vaccine platform. We found that wild-type Ebola virus glycoprotein, in the context of this platform, provides robust protection of EBOV-challenged mice. Further, we found that removal of the heavy glycan shield surrounding conserved regions of the glycoprotein does not enhance vaccine efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
- Author
-
Howell, Katie A., Brannan, Jennifer M., Bryan, Christopher, McNeal, Andrew, Davidson, Edgar, Turner, Hannah L., Vu, Hong, Shulenin, Sergey, He, Shihua, Kuehne, Ana, Herbert, Andrew S., Qiu, Xiangguo, Doranz, Benjamin J., Holtsberg, Frederick W., Ward, Andrew B., Dye, John M., and Aman, M. Javad
- Abstract
Summary Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing and non-neutralizing anti-ebolavirus monoclonal antibodies, whose combination exhibited new functional profiles, including transforming a non-neutralizing antibody to a neutralizer. Sub-neutralizing concentrations of antibodies 2G4 or m8C4 enabled non-neutralizing antibody FVM09 (IC 50 >1 μM) to exhibit potent neutralization (IC 50 1–10 nM). While FVM09 or m8C4 alone failed to protect Ebola-virus-infected mice, a combination of the two antibodies provided 100% protection. Furthermore, non-neutralizers FVM09 and FVM02 exponentially enhanced the potency of two neutralizing antibodies against both Ebola and Sudan viruses. We identified a hotspot for the binding of these enabling antibody pairs near the interface of the glycan cap and GP2. Enabling cooperativity may be an underappreciated phenomenon for viruses, with implications for the design and development of immunotherapeutics and vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.
- Author
-
Kash, John C., Walters, Kathie-Anne, Kindrachuk, Jason, Baxter, David, Scherler, Kelsey, Janosko, Krisztina B., Adams, Rick D., Herbert, Andrew S., James, Rebekah M., Stonier, Spencer W., Memoli, Matthew J., Dye, John M., Davey Jr., Richard T., Chertow, Daniel S., and Taubenberger, Jeffery K.
- Subjects
IMMUNE response ,EBOLA virus disease ,GENE expression ,HEMORRHAGIC fever ,VIRUS diseases ,LEUCOCYTES - Abstract
The article presents a study which shows that marked shifts in immune and antiviral responses that preceded changes in medical condition indicates clearance of replicating Ebola virus from peripheral blood leukocytes which is significant for systemic viral clearance. The measureement of host gene expression by microarray in daily peripheral blood samples collected from a patient with severe Ebola virus disease is mentioned.
- Published
- 2017
- Full Text
- View/download PDF
27. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
- Author
-
Howell, Katie A., Qiu, Xiangguo, Brannan, Jennifer M., Bryan, Christopher, Davidson, Edgar, Holtsberg, Frederick W., Wec, Anna Z., Shulenin, Sergey, Biggins, Julia E., Douglas, Robin, Enterlein, Sven G., Turner, Hannah L., Pallesen, Jesper, Murin, Charles D., He, Shihua, Kroeker, Andrea, Vu, Hong, Herbert, Andrew S., Fusco, Marnie L., and Nyakatura, Elisabeth K.
- Abstract
Summary Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles.
- Author
-
Ndungo, Esther, Herbert, Andrew S., Raaben, Matthijs, Obernosterer, Gregor, Biswas, Rohan, Miller, Emily Happy, Wirchnianski, Ariel S., Carette, Jan E., Brummelkamp, Thijn R., Whelan, Sean P., Dye, John M., and Chandran, Kartik
- Published
- 2016
- Full Text
- View/download PDF
29. Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats.
- Author
-
Melinda Ng, Ndungo, Esther, Kaczmarek, Maria E., Herbert, Andrew S., Binger, Tabea, Kuehne, Ana I., Jangra, Rohit K., Hawkins, John A., Gifford, Robert J., Biswas, Rohan, Demogines, Ann, James, Rebekah M., Meng Yu, Brummelkamp, Thijn R., Drosten, Christian, Lin-Fa Wang, Kuhn, Jens H., Müller, Marcel A., Dye, John M., and Sawyer, Sara L.
- Published
- 2015
- Full Text
- View/download PDF
30. Immune Memory to Sudan Virus: Comparison between Two Separate Disease Outbreaks.
- Author
-
Sobarzo, Ariel, Eskira, Yael, Herbert, Andrew S., Kuehne, Ana I., Stonier, Spencer W., Ochayon, David E., Fedida-Metula, Shlomit, Balinandi, Steven, Kislev, Yaara, Tali, Neta, Lewis, Eli C., Lutwama, Julius Julian, Dye, John M., Yavelsky, Victoria, and Lobel, Leslie
- Subjects
IMMUNOLOGIC memory ,DISEASE outbreaks ,EBOLA virus ,MICROBIOLOGY education ,MEMORY disorders - Abstract
Recovery from ebolavirus infection in humans is associated with the development of both cell-mediated and humoral immune responses. According to recent studies, individuals that did not survive infection with ebolaviruses appear to have lacked a robust adaptive immune response and the expression of several early innate response markers. However, a comprehensive protective immune profile has yet to be described. Here, we examine cellular memory immune responses among survivors of two separate Ebolavirus outbreaks (EVDs) due to Sudan virus (SUDV) infection in Uganda-Gulu 2000-2001 and Kibaale 2012. Freshly collected blood samples were stimulated with inactivated SUDV, as well as with recombinant SUDV or Ebola virus (EBOV) GP (GP1-649). In addition, ELISA and plaque reduction neutralization assays were performed to determine anti-SUDV IgG titers and neutralization capacity. Cytokine expression was measured in whole blood cultures in response to SUDV and SUDV GP stimulation in both survivor pools, demonstrating recall responses that indicate immune memory. Cytokine responses between groups were similar but had distinct differences. Neutralizing, SUDV-specific IgG activity against irradiated SUDV and SUDV recombinant proteins were detected in both survivor cohorts. Furthermore, humoral and cell-mediated crossreactivity to EBOV and EBOV recombinant GP1-649 was observed in both cohorts. In conclusion, immune responses in both groups of survivors demonstrate persistent recognition of relevant antigens, albeit larger cohorts are required in order to reach greater statistical significance. The differing cytokine responses between Gulu and Kibaale outbreak survivors suggests that each outbreak may not yield identical memory responses and promotes the merits of studying the immune responses among outbreaks of the same virus. Finally, our demonstration of cross-reactive immune recognition suggests that there is potential for developing cross-protective vaccines for ebolaviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
- Author
-
Uprichard, Susan L., O'Brien, Amornrat, Evdokimova, Monika, Rowe, Cynthia L., Joyce, Cara, Hackbart, Matthew, Cruz-Pulido, Yazmin E., Cohen, Courtney A., Rock, Michelle L., Dye, John M., Kuehnert, Paul, Ricks, Keersten M., Casper, Marybeth, Linhart, Lori, Anderson, Katrina, Kirk, Laura, Maggiore, Jack A., Herbert, Andrew S., Clark, Nina M., and Reid, Gail E.
- Subjects
ANTIBODY formation ,VACCINATION ,SARS-CoV-2 ,VACCINE effectiveness ,COVID-19 pandemic - Abstract
Understanding the magnitude of responses to vaccination during the ongoing SARS-CoV-2 pandemic is essential for ultimate mitigation of the disease. Here, we describe a cohort of 102 subjects (70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of one of the mRNA vaccines (BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna)). We document that a single exposure to antigen via infection or vaccination induces a variable antibody response which is affected by age, gender, race, and co-morbidities. In response to a second antigen dose, both COVID-19-naïve and experienced subjects exhibited elevated levels of anti-spike and SARS-CoV-2 neutralizing activity; however, COVID-19-experienced individuals achieved higher antibody levels and neutralization activity as a group. The COVID-19-experienced subjects exhibited no significant increase in antibody or neutralization titer in response to the second vaccine dose (i.e., third antigen exposure). Finally, we found that COVID-19-naïve individuals who received the Moderna vaccine exhibited a more robust boost response to the second vaccine dose (p = 0.004) as compared to the response to Pfizer–BioNTech. Ongoing studies with this cohort will continue to contribute to our understanding of the range and durability of responses to SARS-CoV-2 mRNA vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus.
- Author
-
Herbert, Andrew S., Kuehne, Ana I., Barth, James F., Ortiz, Ramon A., Nichols, Donald K., Zak, Samantha E., Stonier, Spencer W., Muhammad, Majidat A., Bakken, Russell R., Prugar, Laura I., Olinger, Gene G., Groebner, Jennifer L., Lee, John S., Pratt, William D., Custer, Max, Kamrud, Kurt I., Smith, Jonathan F., Hart, Mary Kate, and Dye, John M.
- Subjects
- *
VENEZUELAN equine encephalomyelitis , *VIRAL replicons , *VIRAL vaccines , *EBOLA virus disease prevention , *MARBURG virus disease , *GLYCOPROTEINS , *GENE expression , *INTRAMUSCULAR injections - Abstract
There are no vaccines or therapeutics currently approved for the prevention or treatment of ebolavirus infection. Previously, a replicon vaccine based on Venezuelan equine encephalitis virus (VEEV) demonstrated protective efficacy against Marburg virus in nonhuman primates. Here, we report the protective efficacy of Sudan virus (SUDV)- and Ebola virus (EBOV)-specific VEEV replicón particle ( VRP) vaccines in nonhuman primates. VRP vaccines were developed to express the glycoprotein (GP) of either SUDV or EBOV. A single intramuscular vaccination of cynomolgus macaques with VRP expressing SUDV GP provided com-plete protection against intramuscular challenge with SUDV. Vaccination against SUDV and subsequent survival of SUDV challenge did not fully protect cynomolgus macaques against intramuscular EBOV back-challenge. However, a single simultaneous intramuscular vaccination with VRP expressing SUDV GP combined with VRP expressing EBOV GP did provide complete protection against intramuscular challenge with either SUDV or EBOV in cynomolgus macaques. Finally, intramuscular vaccination with VRP expressing SUDV GP completely protected cynomolgus macaques when challenged with aerosolized SUDV, although complete protection against aerosol challenge required two vaccinations with this vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. Niemann-Pick C1 (NPC1)/NPC1-like1 Chimeras Define Sequences Critical for NPC1's Function as a Filovirus Entry Receptor.
- Author
-
Krishnan, Anuja, Miller, Emily Happy, Herbert, Andrew S., Melinda, Ng, Ndungo, Esther, Whelan, Sean P., Dye, John M., and Chandran, Kartik
- Subjects
EBOLA virus ,MARBURG virus ,NIEMANN-Pick diseases ,VIRAL receptors ,CHIMERISM ,HEPATITIS C virus - Abstract
We recently demonstrated that Niemann-Pick C1 (NPC1), a ubiquitous 13-pass cellular membrane protein involved in lysosomal cholesterol transport, is a critical entry receptor for filoviruses. Here we show that Niemann-Pick C1-like1 (NPC1L1), an NPC1 paralog and hepatitis C virus entry factor, lacks filovirus receptor activity. We exploited the structural similarity between NPC1 and NPC1L1 to construct and analyze a panel of chimeras in which NPC1L1 sequences were replaced with cognate sequences from NPC1. Only one chimera, NPC1L1 containing the second luminal domain (C) of NPC1 in place of its own, bound to the viral glycoprotein, GP. This engineered protein mediated authentic filovirus infection nearly as well as wild-type NPC1, and more efficiently than did a minimal NPC1 domain C-based receptor recently described by us. A reciprocal chimera, NPC1 containing NPC1L1's domain C, was completely inactive. Remarkably, an intra-domain NPC1L1-NPC1 chimera bearing only a ∼130-amino acid N-terminal region of NPC1 domain C could confer substantial viral receptor activity on NPC1L1. Taken together, these findings account for the failure of NPC1L1 to serve as a filovirus receptor, highlight the central role of the luminal domain C of NPC1 in filovirus entry, and reveal the direct involvement of N-terminal domain C sequences in NPC1's function as a filovirus receptor [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Ebola virus entry requires the host-programmed recognition of an intracellular receptor.
- Author
-
Miller, Emily Happy, Obernosterer, Gregor, Raaben, Matthijs, Herbert, Andrew S, Deffieu, Maika S, Krishnan, Anuja, Ndungo, Esther, Sandesara, Rohini G, Carette, Jan E, Kuehne, Ana I, Ruthel, Gordon, Pfeffer, Suzanne R, Dye, John M, Whelan, Sean P, Brummelkamp, Thijn R, and Chandran, Kartik
- Subjects
EBOLA virus ,MOLECULAR recognition ,ETIOLOGY of diseases ,CHOLESTEROL ,MEMBRANE proteins ,CYTOPLASM ,BINDING sites - Abstract
Ebola and Marburg filoviruses cause deadly outbreaks of haemorrhagic fever. Despite considerable efforts, no essential cellular receptors for filovirus entry have been identified. We showed previously that Niemann-Pick C1 (NPC1), a lysosomal cholesterol transporter, is required for filovirus entry. Here, we demonstrate that NPC1 is a critical filovirus receptor. Human NPC1 fulfills a cardinal property of viral receptors: it confers susceptibility to filovirus infection when expressed in non-permissive reptilian cells. The second luminal domain of NPC1 binds directly and specifically to the viral glycoprotein, GP, and a synthetic single-pass membrane protein containing this domain has viral receptor activity. Purified NPC1 binds only to a cleaved form of GP that is generated within cells during entry, and only viruses containing cleaved GP can utilize a receptor retargeted to the cell surface. Our findings support a model in which GP cleavage by endosomal cysteine proteases unmasks the binding site for NPC1, and GP-NPC1 engagement within lysosomes promotes a late step in entry proximal to viral escape into the host cytoplasm. NPC1 is the first known viral receptor that recognizes its ligand within an intracellular compartment and not at the plasma membrane. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
35. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.
- Author
-
Herbert, Andrew S., Heffron, Lynn, Sundick, Roy, and Roberts, Paul C.
- Subjects
- *
IMMUNOREGULATION , *INFLUENZA vaccines , *INFLUENZA viruses , *CELL lines , *HEMAGGLUTININ , *CYTOKINES - Abstract
Background: Influenza epidemics continue to cause morbidity and mortality within the human population despite widespread vaccination efforts. This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. We have developed an in vitro model system for producing a membrane-bound Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines and other immunomodulatory proteins to create a more immunogenic vaccine. Results: We have evaluated the immunogenicity of inactivated cytokine-bearing influenza vaccines using a mouse model of lethal influenza virus challenge. CYT-IVACs were produced by stably transfecting MDCK cell lines with mouse-derived cytokines (GM-CSF, IL-2 and IL-4) fused to the membrane-anchoring domain of the viral hemagglutinin. Influenza virus replication in these cell lines resulted in the uptake of the bioactive membrane-bound cytokines during virus budding and release. In vivo efficacy studies revealed that a single low dose of IL-2 or IL-4-bearing CYT-IVAC is superior at providing protection against lethal influenza challenge in a mouse model and provides a more balanced Th1/Th2 humoral immune response, similar to live virus infections. Conclusion: We have validated the protective efficacy of CYT-IVACs in a mammalian model of influenza virus infection. This technology has broad applications in current influenza virus vaccine development and may prove particularly useful in boosting immune responses in the elderly, where current vaccines are minimally effective. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
36. Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo
- Author
-
Herbert, Andrew S., Davidson, Cristin, Kuehne, Ana I., Bakken, Russell, Braigen, Stephen Z., Gunn, Kathryn E., Whelan, Sean P., Brummelkamp, Thijn R., Twenhafel, Nancy A., Chandran, Kartik, Walkley, Steven U., and Dye, John M.
- Abstract
Recent work demonstrated that the Niemann-Pick C1 (NPC1) protein is an essential entry receptor for filoviruses. While previous studies focused on filovirus entry requirements of NPC1 in vitro, its roles in filovirus replication and pathogenesis in vivo remain unclear. Here, we evaluated the importance of NPC1, and its partner in cholesterol transport, NPC2, by using a mouse model of Ebolavirus (EBOV) disease. We found that, whereas wild-type mice had high viral loads and succumbed to EBOV infection, Npc1−/− mice were entirely free of viral replication and completely protected from EBOV disease. Interestingly, Npc1+/− mice transiently developed high levels of viremia, but were nevertheless substantially protected from EBOV challenge. We also found Npc2−/− mice to be fully susceptible to EBOV infection, while Npc1−/− mice treated to deplete stored lysosomal cholesterol remained completely resistant to EBOV infection. These results provide mechanistic evidence that NPC1 is directly required for EBOV infection in vivo, with little or no role for NPC1/NPC2-dependent cholesterol transport. Finally, we assessed the in vivo antiviral efficacies of three compounds known to inhibit NPC1 function or NPC1-glycoprotein binding in vitro. Two compounds reduced viral titers in vivo and provided a modest, albeit not statistically significant, degree of protection. Taken together, our results show that NPC1 is critical for replication and pathogenesis in animals and is a bona fide target for development of antifilovirus therapeutics. Additionally, our findings with Npc1+/− mice raise the possibility that individuals heterozygous for NPC1 may have a survival advantage in the face of EBOV infection.
- Published
- 2015
- Full Text
- View/download PDF
37. Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names
- Author
-
Kuhn, Jens H., Andersen, Kristian G., Bào, Yīmíng, Bavari, Sina, Becker, Stephan, Bennett, Richard S., Bergman, Nicholas H., Blinkova, Olga, Bradfute, Steven, Brister, J. Rodney, Bukreyev, Alexander, Chandran, Kartik, Chepurnov, Alexander A., Davey, Robert A., Dietzgen, Ralf G., Doggett, Norman A., Dolnik, Olga, Dye, John M., Enterlein, Sven, Fenimore, Paul W., Formenty, Pierre, Freiberg, Alexander N., Garry, Robert F., Garza, Nicole L., Gire, Stephen K., Gonzalez, Jean-Paul, Griffiths, Anthony, Happi, Christian T., Hensley, Lisa E., Herbert, Andrew S., Hevey, Michael C., Hoenen, Thomas, Honko, Anna N., Ignatyev, Georgy M., Jahrling, Peter B., Johnson, Joshua C., Johnson, Karl M., Kindrachuk, Jason, Klenk, Hans-Dieter, Kobinger, Gary, Kochel, Tadeusz J., Lackemeyer, Matthew G., Lackner, Daniel F., Leroy, Eric M., Lever, Mark S., Mühlberger, Elke, Netesov, Sergey V., Olinger, Gene G., Omilabu, Sunday A., Palacios, Gustavo, Panchal, Rekha G., Park, Daniel J., Patterson, Jean L., Paweska, Janusz T., Peters, Clarence J., Pettitt, James, Pitt, Louise, Radoshitzky, Sheli R., Ryabchikova, Elena I., Saphire, Erica Ollmann, Sabeti, Pardis C., Sealfon, Rachel, Shestopalov, Aleksandr M., Smither, Sophie J., Sullivan, Nancy J., Swanepoel, Robert, Takada, Ayato, Towner, Jonathan S., van der Groen, Guido, Volchkov, Viktor E., Volchkova, Valentina A., Wahl-Jensen, Victoria, Warren, Travis K., Warfield, Kelly L., Weidmann, Manfred, and Nichol, Stuart T.
- Subjects
Bundibugyo virus ,cDNA clone ,cuevavirus ,Ebola ,Ebola virus ,ebolavirus ,filovirid ,filovirus ,genome annotation ,ICTV ,International Committee on Taxonomy of Viruses ,Lloviu virus ,Marburg virus ,marburgvirus ,mononegavirad ,mononegavirus ,Ravn virus ,RefSeq ,Reston virus ,reverse genetics ,Sudan virus ,Taï Forest virus ,virus classification ,virus isolate ,virus nomenclature ,virus strain ,virus taxonomy ,virus variant - Abstract
Sequence determination of complete or coding-complete genomes of viruses is becoming common practice for supporting the work of epidemiologists, ecologists, virologists, and taxonomists. Sequencing duration and costs are rapidly decreasing, sequencing hardware is under modification for use by non-experts, and software is constantly being improved to simplify sequence data management and analysis. Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including characterization of the evolution of individual virus populations in single patients over time. The increasing accumulation of sequencing data creates a management problem for the curators of commonly used sequence databases and an entry retrieval problem for end users. Therefore, utilizing the data to their fullest potential will require setting nomenclature and annotation standards for virus isolates and associated genomic sequences. The National Center for Biotechnology Information’s (NCBI’s) RefSeq is a non-redundant, curated database for reference (or type) nucleotide sequence records that supplies source data to numerous other databases. Building on recently proposed templates for filovirus variant naming [
( )/ / / / - ], we report consensus decisions from a majority of past and currently active filovirus experts on the eight filovirus type variants and isolates to be represented in RefSeq, their final designations, and their associated sequences. - Published
- 2014
- Full Text
- View/download PDF
38. Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.
- Author
-
Froude, Jeffrey W., Herbert, Andrew S., Pelat, Thibaut, Miethe, Sebastian, Zak, Samantha E., Brannan, Jennifer M., Bakken, Russell R., Steiner, Alexander R., Yin, Gang, Hallam, Trevor J., Sato, Aaron K., Hust, Michael, Thullier, Philippe, and Dye, John M.
- Subjects
- *
VIRAL antibodies , *LABORATORY mice , *GLYCOPROTEIN genetics , *KRA , *IMMUNIZATION , *IMMUNOGLOBULIN genetics ,TREATMENT of Ebola virus diseases - Abstract
Sudan virus (SUDV) and Ebola viruses (EBOV) are both members of the
Ebolavirus genus and have been sources of epidemics and outbreaks for several decades. We present here the generation and characterization of cross-reactive antibodies to both SUDV and EBOV, which were produced in a cell-free system and protective against SUDV in mice. A non-human primate, cynomolgus macaque, was immunized with viral-replicon particles expressing the glycoprotein of SUDV-Boniface (8A). Two separate antibody fragment phage display libraries were constructed after four immunogen injections. Both libraries were screened first against the SUDV and a second library was cross-selected against EBOV-Kikwit. Sequencing of 288 selected clones from the two distinct libraries identified 58 clones with distinct VH and VL sequences. Many of these clones were cross-reactive to EBOV and SUDV and able to neutralize SUDV. Three of these recombinant antibodies (X10B1, X10F3, and X10H2) were produced in the scFv-Fc format utilizing a cell-free production system. Mice that were challenged with SUDV-Boniface receiving 100µg of the X10B1/X10H2 scFv-Fc combination 6 and 48-h post-exposure demonstrated partial protection individually and complete protection as a combination. The data herein suggests these antibodies may be promising candidates for further therapeutic development. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
- Author
-
Wec, Anna Z., Herbert, Andrew S., Murin, Charles D., Nyakatura, Elisabeth K., Abelson, Dafna M., Fels, J. Maximilian, He, Shihua, James, Rebekah M., de La Vega, Marc-Antoine, Zhu, Wenjun, Bakken, Russell R., Goodwin, Eileen, Turner, Hannah L., Jangra, Rohit K., Zeitlin, Larry, Qiu, Xiangguo, Lai, Jonathan R., Walker, Laura M., Ward, Andrew B., and Dye, John M.
- Subjects
- *
VIRAL antibodies , *GLYCOPROTEINS , *VIRUS virulence , *ENDOSOMES ,TREATMENT of Ebola virus diseases - Abstract
Summary Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GP CL ) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GP CL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.
- Author
-
Dye, John M., Wu, Hua, Hooper, Jay W., Khurana, Surender, Kuehne, Ana I., Coyle, Elizabeth M., Ortiz, Ramon A., Fuentes, Sandra, Herbert, Andrew S., Golding, Hana, Bakken, Russell A., Brannan, Jennifer M., Kwilas, Steve A., Sullivan, Eddie J., Luke, Thomas C., Smith, Gale, Glenn, Gregory, Li, Wenfang, Ye, Ling, and Yang, Chinglai
- Published
- 2016
- Full Text
- View/download PDF
41. A“Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses.
- Author
-
Wec, Anna Z., Nyakatura, Elisabeth K., Herbert, Andrew S., Howell, Katie A., Holtsberg, Frederick W., Bakken, Russell R., Mittler, Eva, Christin, John R., Shulenin, Sergey, Jangra, Rohit K., Bharrhan, Sushma, Kuehne, Ana I., Bornholdt, Zachary A., Flyak, Andrew I., Saphire, Erica Ollmann, Crowe Jr., James E., Aman, M. Javad, Dye, John M., Lai, Jonathan R., and Chandran, Kartik
- Subjects
- *
BISPECIFIC antibodies , *EBOLA virus , *GLYCOPROTEINS , *EPITOPES , *IMMUNOTHERAPY - Abstract
There is an urgent need for monoclonal antibody (mAb) therapies that broadly protect against Ebola virus and other filoviruses. The conserved, essential interaction between the filovirus glycoprotein, GP, and its entry receptor Niemann-Pick C1 (NPC1) provides an attractive target for such mAbs but is shielded by multiple mechanisms, including physical sequestration in late endosomes. Here, we describe a bispecific-antibody strategy to target this interaction, in which mAbs specific for NPC1 or the GP receptor–binding site are coupled to a mAb against a conserved, surface-exposed GP epitope. Bispecific antibodies, but not parent mAbs, neutralized all known ebolaviruses by coopting viral particles themselves for endosomal delivery and conferred postexposure protection against multiple ebolaviruses in mice. Such “Trojan horse” bispecific antibodies have potential as broad antifilovirus immunotherapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
- Author
-
Gupta, Yash, Maciorowski, Dawid, Zak, Samantha E., Jones, Krysten A., Kathayat, Rahul S., Azizi, Saara-Anne, Mathur, Raman, Pearce, Catherine M, Ilc, David J., Husein, Hamza, Herbert, Andrew S., Bharti, Ajay, Rathi, Brijesh, Durvasula, Ravi, Becker, Daniel P., Dickinson, Bryan C., Dye, John M., and Kempaiah, Prakasha
- Subjects
- *
MOLECULAR dynamics , *PROTEIN kinase C , *DNA helicases , *COVID-19 , *INVESTIGATIONAL drugs , *SARS-CoV-2 - Abstract
• Seven enzymes of Covid19 virus proteome were comprehensively targeted; 3CLPro, PlPro, RdRP, Helicase, NandoU, ExoN and 2O-MT. • Virtual screening (VS) was performed with world approved/investigational drug libraries (n = 5903). • Two tier anti-viral assay with nuclei counting for reliable activity. • Bisindolylmaleimide IX reported here is an advanced investigational molecule and has 80% viral blocking at 50 µM. • Specific highly sensitive FRET based main protease (3ClPro) enzymatic assays. • This drug discovery effort solely targets to understand drug targetability of Covid-19 as well as to enrich the candidates for future drugs that have acceptable/investigated safety profiles. SARS-CoV-2, the virus that causes COVID-19 consists of several enzymes with essential functions within its proteome. Here, we focused on repurposing approved and investigational drugs/compounds. We targeted seven proteins with enzymatic activities known to be essential at different stages of the viral cycle including PLpro, 3CLpro, RdRP, Helicase, ExoN, NendoU, and 2′-O-MT. For virtual screening, energy minimization of a crystal structure of the modeled protein was carried out using the Protein Preparation Wizard (Schrodinger LLC 2020-1). Following active site selection based on data mining and COACH predictions, we performed a high-throughput virtual screen of drugs and investigational molecules (n = 5903). The screening was performed against viral targets using three sequential docking modes (i.e., HTVS, SP, and XP). Virtual screening identified ∼290 potential inhibitors based on the criteria of energy, docking parameters, ligand, and binding site strain and score. Drugs specific to each target protein were further analyzed for binding free energy perturbation by molecular mechanics (prime MM-GBSA) and pruning the hits to the top 32 candidates. The top lead from each target pool was further subjected to molecular dynamics simulation using the Desmond module. The resulting top eight hits were tested for their SARS-CoV-2 anti-viral activity in-vitro. Among these, a known inhibitor of protein kinase C isoforms, Bisindolylmaleimide IX (BIM IX), was found to be a potent inhibitor of SARS-CoV-2. Further, target validation through enzymatic assays confirmed 3CLpro to be the target. This is the first study that has showcased BIM IX as a COVID-19 inhibitor thereby validating our pipeline. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.
- Author
-
Fels, J. Maximilian, Maurer, Daniel P., Herbert, Andrew S., Wirchnianski, Ariel S., Vergnolle, Olivia, Cross, Robert W., Abelson, Dafna M., Moyer, Crystal L., Mishra, Akaash K., Aguilan, Jennifer T., Kuehne, Ana I., Pauli, Noel T., Bakken, Russell R., Nyakatura, Elisabeth K., Hellert, Jan, Quevedo, Gregory, Lobel, Leslie, Balinandi, Stephen, Lutwama, Julius J., and Zeitlin, Larry
- Subjects
- *
HEMORRHAGIC fever , *MONOCLONAL antibodies , *BISPECIFIC antibodies , *IMMUNOGLOBULINS , *GLYCOPROTEINS , *IMMUNE response - Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific treatments and vaccines are urgently needed. Here, we characterize the human immune response to natural CCHFV infection to identify potent neutralizing monoclonal antibodies (nAbs) targeting the viral glycoprotein. Competition experiments showed that these nAbs bind six distinct antigenic sites in the Gc subunit. These sites were further delineated through mutagenesis and mapped onto a prefusion model of Gc. Pairwise screening identified combinations of non-competing nAbs that afford synergistic neutralization. Further enhancements in neutralization breadth and potency were attained by physically linking variable domains of synergistic nAb pairs through bispecific antibody (bsAb) engineering. Although multiple nAbs protected mice from lethal CCHFV challenge in pre- or post-exposure prophylactic settings, only a single bsAb, DVD-121-801, afforded therapeutic protection. DVD-121-801 is a promising candidate suitable for clinical development as a CCHFV therapeutic. [Display omitted] • 361 monoclonal antibodies against CCHFV glycoproteins isolated from human survivors • Potent and broad neutralizers targeting six antigenic sites in Gc identified • Specific combinations of noncompeting antibodies afford synergistic neutralization • Bispecific antibody combining synergistic antibodies confers therapeutic protection By isolating monoclonal antibodies against Crimean-Congo hemorrhagic fever virus glycoproteins from human survivors, Fels et al. were able to identify combinations of synergistic neutralizing antibodies and engineer bispecific antibodies that provide therapeutic protection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy.
- Author
-
Gupta, Yash, Maciorowski, Dawid, Zak, Samantha E., Kulkarni, Chandrashekhar V., Herbert, Andrew S., Durvasula, Ravi, Fareed, Jawed, Dye, John M., and Kempaiah, Prakasha
- Subjects
- *
LIGHT transmission , *HEPARIN , *SARS-CoV-2 , *HIGH throughput screening (Drug development) , *COVID-19 , *MOLARS , *EYELIDS - Abstract
The world is currently facing a novel coronavirus (SARS-CoV-2) pandemic. The greatest threat that is disrupting the normal functioning of society is the exceptionally high species independent transmission. Drug repurposing is understood to be the best strategy to immediately deploy well-characterized agents against new pathogens. Several repurposable drugs are already in evaluation for determining suitability to treat COVID-19. One such promising compound includes heparin, which is widely used in reducing thrombotic events associated with COVID-19 induced pathology. As part of identifying target-specific antiviral compounds among FDA and world-approved libraries using high-throughput virtual screening (HTVS), we previously evaluated top hits for anti -SARS-CoV-2 activity. Here, we report results of highly efficacious viral entry blocking properties of heparin (IC 50 = 12.3 nM) in the complete virus assay, and further, propose ways to use it as a potential transmission blocker. Exploring further, our in-silico analysis indicated that the heparin interacts with post-translational glycoconjugates present on spike proteins. The patterns of accessible spike-glycoconjugates in open and closed states are completely contrasted by one another. Heparin-binding to the open conformation of spike structurally supports the state and may aid ACE2 binding as reported with cell surface-bound heparan sulfate. We also studied spike protein mutant variants' heparin interactions for possible resistance. Based on available data and optimal absorption properties by the skin, heparin could potentially be used to block SARS-CoV-2 transmission. Studies should be designed to exploit its nanomolar antiviral activity to formulate heparin as topical or inhalation-based formulations, particularly on exposed areas and sites of primary viremia e.g. ACE2 rich epithelia of the eye (conjunctiva/lids), nasal cavity, and mouth. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
- Author
-
Holtsberg, Frederick W., Shulenin, Sergey, Hong Vu, Howell, Katie A., Patel, Sonal J., Gunn, Bronwyn, Karim, Marcus, Lai, Jonathan R., Frei, Julia C., Nyakatur, Elisabeth K., Zeitlin, Larry, Douglas, Robin, Fusco, Marnie L., Froude, Jeffrey W., Saphire, Erica Ollmann, Herbert, Andrew S., Wirchnianski, Ariel S., Lear-Rooney, Calli M., Alter, Galit, and Dye, John M.
- Subjects
- *
EBOLA virus disease , *EPIDEMICS , *FILOVIRIDAE , *MONOCLONAL antibodies , *GLYCOPROTEINS - Abstract
The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has highlighted the need for effective therapeutics against filoviruses. Monoclonal antibody (MAb) cocktails have shown great potential as EVD therapeutics; however, the existing protective MAbs are virus species specific. Here we report the development of pan-ebolavirus and pan-filovirus antibodies generated by repeated immunization of mice with filovirus glycoproteins engineered to drive the B cell responses toward conserved epitopes. Multiple pan-ebolavirus antibodies were identified that react to the Ebola, Sudan, Bundibugyo, and Reston viruses. A pan-filovirus antibody that was reactive to the receptor binding regions of all filovirus glycoproteins was also identified. Significant postexposure efficacy of several MAbs, including a novel antibody cocktail, was demonstrated. For the first time, we report cross-neutralization and in vivo protection against two highly divergent filovirus species, i.e., Ebola virus and Sudan virus, with a single antibody. Competition studies indicate that this antibody targets a previously unrecognized conserved neutralizing epitope that involves the glycan cap. Mechanistic studies indicated that, besides neutralization, innate immune cell effector functions may play a role in the antiviral activity of the antibodies. Our findings further suggest critical novel epitopes that can be utilized to design effective cocktails for broad protection against multiple filovirus species. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
- Author
-
Zhen-Yong Keck, Enterlein, Sven G., Howell, Katie A., Vu, Hong, Shulenin, Sergey, Warfield, Kelly L., Froude, Jeffrey W., Araghi, Nazli, Douglas, Robin, Biggins, Julia, Lear-Rooney, Calli M., Wirchnianski, Ariel S., Lau, Patrick, Yong Wang, Herbert, Andrew S., Dye, John M., Glass, Pamela J., Holtsberg, Frederick W., Foung, Steven K. H., and Aman, M. Javad
- Subjects
- *
FILOVIRIDAE , *IMMUNOTHERAPY , *MONOCLONAL antibodies , *IMMUNOGLOBULINS - Abstract
Filoviruses cause highly lethal viral hemorrhagic fever in humans and nonhuman primates. Current immunotherapeutic options for filoviruses are mostly specific to Ebola virus (EBOV), although other members of Filoviridae such as Sudan virus (SUDV), Bundibugyo virus (BDBV), and Marburg virus (MARV) have also caused sizeable human outbreaks. Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filovirus species. The antibodies recognize novel neutralizing and nonneutralizing epitopes on the filovirus glycoprotein, including conserved conformational epitopes within the core regions of the GP1 subunit and a novel linear epitope within the glycan cap. We further report the first filovirus antibody binding to a highly conserved epitope within the fusion loop of ebolavirus and marburgvirus species. One of the antibodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cross neutralized both SUDV and EBOV, the most divergent ebolavirus species. In a mouse model of EBOV infection, this antibody provided 100% protection when administered in two doses and partial, but significant, protection when given once at the peak of viremia 3 days postinfection. Furthermore, we describe novel cocktails of antibodies with enhanced protective efficacy compared to individual MAbs. In summary, the present work describes multiple novel, cross-reactive filovirus epitopes and innovative combination concepts that challenge the current therapeutic models. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
- Author
-
Gupta, Yash, Kumar, Sumit, Zak, Samantha E., Jones, Krysten A., Upadhyay, Charu, Sharma, Neha, Azizi, Saara-Anne, Kathayat, Rahul S., Poonam, Herbert, Andrew S., Durvasula, Ravi, Dickinson, Bryan C., Dye, John M., Rathi, Brijesh, and Kempaiah, Prakasha
- Subjects
- *
SARS-CoV-2 , *HIGH throughput screening (Drug development) , *PROTEOLYTIC enzymes , *COVID-19 , *DATABASES , *STRAIN energy - Abstract
[Display omitted] The continued toll of COVID-19 has halted the smooth functioning of civilization on a global scale. With a limited understanding of all the essential components of viral machinery and the lack of structural information of this new virus, initial drug discovery efforts had limited success. The availability of high-resolution crystal structures of functionally essential SARS-CoV-2 proteins, including 3CLpro, supports the development of target-specific therapeutics. 3CLpro, the main protease responsible for the processing of viral polypeptide, plays a vital role in SARS-CoV-2 viral replication and translation and is an important target in other coronaviruses. Additionally, 3CLpro is the target of repurposed drugs, such as lopinavir and ritonavir. In this study, target proteins were retrieved from the protein data bank (PDB IDs: 6 M03, 6LU7, 2GZ7, 6 W63, 6SQS, 6YB7, and 6YVF) representing different open states of the main protease to accommodate macromolecular substrate. A hydroxyethylamine (HEA) library was constructed from harvested chemical structures from all the series being used in our laboratories for screening against malaria and Leishmania parasites. The database consisted of ∼1000 structure entries, of which 70% were new to ChemSpider at the time of screening. This in-house library was subjected to high throughput virtual screening (HTVS), followed by standard precision (SP) and then extra precision (XP) docking (Schrodinger LLC 2021). The ligand strain and complex energy of top hits were calculated by Molecular Mechanics Generalized Born Surface Area (MM/GBSA) method. Promising hit compounds (n = 40) specifically binding to 3CLpro with high energy and average MM/GBSA scores were then subjected to (100-ns) MD simulations. Using this sequential selection followed by an in-silico validation approach, we found a promising HEA-based compound (N,N'-((3S,3′S)-piperazine-1,4-diylbis(3-hydroxy-1-phenylbutane-4,2-diyl))bis(2-(5-methyl-1,3-dioxoisoindolin-2-yl)-3-phenylpropanamide)), which showed high in vitro antiviral activity against SARS-CoV-2. Further to reduce the size of the otherwise larger ligand, a pharmacophore-based predicted library of ∼42 derivatives was constructed, which were added to the previous compound library and rescreened virtually. Out of several hits from the predicted library, two compounds were synthesized, tested against SARS-CoV-2 culture, and found to have markedly improved antiviral activity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.